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INFLUENZA VIRUS DISEASE {#jlb0083-sec-0002}
=======================

Influenza infection in humans can cause a wide range of disease symptoms, from asymptomatic to serious illness, characterized by sudden onset of fever, myalgia, and respiratory indications, including nonproductive cough, sore throat, and rhinitis. In addition, children infected with influenza commonly present with otitis media, nausea, and vomiting and more frequently, complain of rhinorrhea \[[1](#B1){ref-type="ref"}, [2](#B2){ref-type="ref"}\]. Historically, the pediatric and elderly populations are considered vulnerable during influenza epidemics \[[3](#B3){ref-type="ref"}, [--](#B4){ref-type="ref"}, [5](#B5){ref-type="ref"}, [6](#B6){ref-type="ref"}\], and although still debated, studies suggest that children have a unique role in the spread of influenza during epidemics \[[7](#B7){ref-type="ref"}, [--](#B8){ref-type="ref"}, [9](#B9){ref-type="ref"}\]. Children under 2 years old are more susceptible to secondary complications \[[10](#B10){ref-type="ref"}\], and infants with severe respiratory tract viral infection are often at greater danger for pulmonary dysfunction, including wheezing, allergy, and asthma later in life \[[11](#B11){ref-type="ref"}, [--](#B12){ref-type="ref"}, [13](#B13){ref-type="ref"}\]. In contrast, elderly individuals are at higher risk for developing hemorrhagic bronchitis, pneumonia, and death when infected with influenza \[[14](#B14){ref-type="ref"}\], and this population generally has a less‐robust immune response following influenza immunization.

Although RSV infections are the leading cause of hospitalizations of children in the United States, influenza accounts for the highest incidence of infection in children under 2 years of age \[[15](#B15){ref-type="ref"}\]. Influenza epidemics occur annually and can cause significant morbidity and mortality worldwide. During 1976--2007, the CDC estimated that in the United States alone, annually, 8.5% (6309) of all "deaths with underlying pneumonia and influenza causes" (74,363) were influenza‐associated, and 2.1% (23,607) of "deaths with underlying respiratory and circulatory causes" (1,132,319) were influenza‐associated \[[16](#B16){ref-type="ref"}\]. Furthermore, individuals with underlying respiratory and cardiac disease or diabetes mellitis, infected with influenza, are often at higher risk for developing hemorrhagic bronchitis or pneumonia and associated comorbidities. In 2008, it was estimated that there were 28,000--111,500 deaths attributable to influenza in children \<5 years of age globally, with developing countries carrying the largest burden \[[17](#B17){ref-type="ref"}\]. In the United States, annual influenza epidemics account for an estimated \$10 billion (12% of the total economic burden) in direct medical costs \[[18](#B18){ref-type="ref"}\] and an estimated \$44--\$163 million in hospitalization costs for children \[[19](#B19){ref-type="ref"}\].

Introduction of a swine‐origin influenza into the human population in 2009 quickly disseminated globally, causing the first pandemic of the 21st century. This novel H1N1 virus, hereafter referred to as A(H1N1)pdm09 \[[20](#B20){ref-type="ref"}\], disproportionately affected children and young adults \[[21](#B21){ref-type="ref"}, [22](#B22){ref-type="ref"}\]. Observed mortality increased between four and 10 times in the pediatric population during the initial wave of A(H1N1)pdm09 infection in 2009 compared with previous influenza seasons \[[23](#B23){ref-type="ref"}\], whereas those individuals born prior to 1950 had pre‐existing, cross‐reactive antibodies against A(H1N1)pdm09 \[[24](#B24){ref-type="ref"}\]. As a result, within the population of those with laboratory‐confirmed A(H1N1)pdm09, 2% were older individuals (\>60 years), whereas 79% were \<30 years old. Risk factors for severe A(H1N1)pdm09 infection are similar to those for seasonal influenza but also include obesity. The majority of the severe or fatal cases have accompanying chronic illnesses, such as cardiac disease, chronic respiratory diseases, and diabetes \[[25](#B25){ref-type="ref"}\]. Several studies suggest that pregnant and postpartum women are at increased risk for complications from infections with A(H1N1)pdm09 \[[26](#B26){ref-type="ref"}, [--](#B27){ref-type="ref"}, [28](#B28){ref-type="ref"}\]. Furthermore, severity of A(H1N1)pdm09 infection was related to the length of time between symptom onset and the initiation of antiviral treatment with NA inhibitors \[[29](#B29){ref-type="ref"}\].

Influenza infections are associated with secondary bacterial infections, or superinfections, most notably, *Streptococcus pneumoniae* and *Staphylococcus aureus* (reviewed in ref. \[[30](#B30){ref-type="ref"}\]). In children, the most common secondary bacterial infections lead to acute otitis media, which is found in 50% of patients with symptomatic influenza infection, with five to six cases observed annually for every 100 children \<2 years of age \[[10](#B10){ref-type="ref"}\]. Since the emergence of A(H1N1)pdm09, approximately one‐third of fatal infections are associated with bacterial coinfection \[[31](#B31){ref-type="ref"}, [32](#B32){ref-type="ref"}\], but this number includes cases where respiratory support is needed, adding to the risk of secondary infections. In fatal cases of those infected by A(H1N1)pdm09, diffuse alveolar damage alone, diffuse alveolar damage associated with necrotizing bronchiolitis, and diffuse alveolar damage with hemorrhage were found, and in most of the cases where necrotizing bronchiolitis was found, the individuals had bacterial coinfections \[[33](#B33){ref-type="ref"}\].

INFLUENZA IMMUNIZATION {#jlb0083-sec-0003}
======================

Vaccination remains an effective and primary preventive strategy to avert influenza infection. The World Health Organization and CDC recommend that children and adults over the age of 6 months receive an influenza vaccination annually \[[34](#B34){ref-type="ref"}\]. Currently, there are three licensed seasonal vaccines administered in the United States: 1) a TIV, administered by i.m. injection; [2](#B2){ref-type="ref"}) a LAIV, delivered intranasally; and 3) an i.d.‐administered TIV preparation \[[35](#B35){ref-type="ref"}\]. Each includes three circulating strains of influenza grown in eggs, reflecting annual surveillance data that predict which strains (A/H1, A/H3, and B) are most likely to be circulating the following season in northern and southern hemispheres. The i.m. TIV is approved for use in children and adults over 6 months of age, whereas the newer i.d. TIV is approved for adults aged 18--64 years. LAIV is approved for use in healthy children and adults between 2 and 49 years of age. The current influenza vaccines work to induce memory recall responses, primarily via humoral immune responses against the HA and NA surface glycoproteins, and HA inhibition antibody responses following immunization correlates with protection against infection \[[36](#B36){ref-type="ref"}, [37](#B37){ref-type="ref"}\].

The main component standardized in influenza vaccines is the HA protein, and it is well‐characterized in safety trials and challenge studies that the amount of HA within the vaccine correlates with level of protection elicited by immunization \[[38](#B38){ref-type="ref"}, [39](#B39){ref-type="ref"}\]. Beginning during the northern hemisphereˈs 2010--2011 influenza season, a vaccine containing 60 μg HA/vaccine strain, as opposed to 15 μg in other preparations, was approved as an alternative TIV for elderly individuals (over age 65 years) \[[35](#B35){ref-type="ref"}\]. Following vaccination, ASCs rapidly proliferate upon antigen exposure, and cell numbers peak 1 week postimmunization in healthy adults and children \[[40](#B40){ref-type="ref"}, [41](#B41){ref-type="ref"}\]. IgG and IgA ASCs decline to low levels by 4--6 weeks postimmunization \[[42](#B42){ref-type="ref"}, [43](#B43){ref-type="ref"}\]. This increase in the total numbers of ASCs corresponds to nAb levels postvaccination, peaking at 4 weeks in adults and children \[[43](#B43){ref-type="ref"}\]. LAIV elicits a strong serum and mucosal influenza‐specific antibody response \[[44](#B44){ref-type="ref"}\], and studies in young children (6--59 months of age) showed that those receiving LAIV had significantly reduced incidence of influenza infection \[[45](#B45){ref-type="ref"}\]. Although limited data exist, influenza‐specific ASCs and nAb titers are increased to a greater degree following TIV immunization compared with LAIV vaccination \[[43](#B43){ref-type="ref"}, [46](#B46){ref-type="ref"}, [47](#B47){ref-type="ref"}\], but the role of neutralization of LAIV occurring in antigen‐experienced individuals is not well understood.

Influenza immunization is effective, and studies in healthy children \<15 years of age have shown TIV efficacies ranging from 31% to 90% (reviewed in ref. \[[48](#B48){ref-type="ref"}\]). Since 2010, universal influenza vaccination is recommended, i.e., for all individuals at least 6 months of age, but traditional efforts remain focused on those individuals at greatest risk of serious disease: young children, elderly, individuals with pulmonary or cardiovascular disorders, and those who are immunocompromised or pregnant \[[35](#B35){ref-type="ref"}\]. Vaccination programs also elicit indirect benefits, including herd immunity, by which immunized individuals protect those who are immunocompromised or other nonvaccinated individuals \[[49](#B49){ref-type="ref"}, [50](#B50){ref-type="ref"}\]. This effect was observed in a retrospective epidemiological study in Japan and the United States examining mortality and influenza vaccination rates between 1949 and 1998 \[[51](#B51){ref-type="ref"}\]. As children have long been considered to have an important role in the spread of influenza during epidemics \[[7](#B7){ref-type="ref"}, [--](#B8){ref-type="ref"}, [9](#B9){ref-type="ref"}\], Japanese officials legislated compulsory vaccination of school‐aged children in 1977, and as the policy changed to optional immunization in 1987, it became clear that mortality rates were inversely correlated with overall vaccination coverage. However, recent reviews of vaccine studies in various populations have concluded that overestimation of the benefits of vaccination is common, particularly within the elderly population \[[52](#B52){ref-type="ref"}, [53](#B53){ref-type="ref"}\], but studies that take into account selection biases do suggest that vaccination is associated with lower risk of hospitalization for pneumonia or influenza, as well as all‐cause mortality \[[52](#B52){ref-type="ref"}, [54](#B54){ref-type="ref"}, [55](#B55){ref-type="ref"}\]. Furthermore, in October 2009, the United States commenced a national influenza H1N1/2009 vaccination campaign, and it is estimated that ∼41.2% and 43% of the U.S. population received the 2009--2010 and 2010--2011 influenza vaccines, respectively \[[56](#B56){ref-type="ref"}\]. Following implementation of this campaign, the frequency of positive influenza cultures reported to the CDC declined quickly. Immunization and herd immunity resulting from prior exposure of A(H1N1)pdm09 likely resulted in decreased cases of influenza during the 2010--2011 influenza season.

Undoubtedly, influenza vaccines can be improved, particularly for the most vulnerable populations. Continuous epidemiological surveillance of circulating influenza strains is required for keeping pace with antigenic drift and shift (reviewed in ref. \[[57](#B57){ref-type="ref"}\]). Antigenic drift is an endless battle, whereby viral variants emerge as a result of point mutations within the viral genome, escaping antibody‐mediated viral neutralization. Whereas many mutations occur throughout the viral genome, the point mutations within the HA or NA proteins can change antibody‐binding domains, such that individuals no longer have adequate, protective B cell memory responses. In contrast, major qualitative changes in antigenicity as a result of antigenic shift occur as a result of genetic reassortment and replacement of one or more influenza gene segments. This, in turn, creates a new influenza virus subtype, to which little or no immunity may exist within the population. Antigenic shift remains a chief concern, in that highly pathogenic influenza viruses could potentially gain efficient human‐to‐human transmission. As influenza viruses frequently undergo antigenic drift and less frequently, shift, a desirable vaccine candidate would be able to induce highly specific, cross‐reactive antibodies and T cell responses.

One strategy used in vaccine improvement includes the use of adjuvant to increase antigen uptake by APCs and enhance cytokine production. Neither of the U.S.‐licensed TIVs nor LAIV include adjuvant, but there are several licensed vaccines available outside of the United States that use oil and water emulsions for seasonal influenza as well as for A/H5N1 (reviewed in ref. \[[58](#B58){ref-type="ref"}\]). For instance, Novartis Vaccines and Diagnostics (Switzerland) manufactures Fluad using MF59 adjuvant, and GlaxoSmithKline Biologicals (Belgium) produces Pandemrix, which includes AS03. Fluad has been used in Europe since 1997 and was recently approved for use in Canada in adults 65 years and older. MF59 and AS03 are both squalene‐based with surfactants included to stabilize the emulsions. Clinical trials of MF59‐adjuvanted vaccines are well‐tolerated and elicit higher antibody responses in adults \[[59](#B59){ref-type="ref"}, [--](#B60){ref-type="ref"}, [61](#B61){ref-type="ref"}\] and in children \[[62](#B62){ref-type="ref"}, [--](#B63){ref-type="ref"}, [64](#B64){ref-type="ref"}\] compared with unadjuvanted vaccine preparations.

The concept of a universal influenza vaccine, where one vaccine elicits protection against multiple influenza subtypes, is becoming a reality. The influenza M2 ion channel is expressed at high levels on the surface of influenza‐infected cells and has a conserved ectodomain (M2e) that is 24 aa in length \[[65](#B65){ref-type="ref"}\]. Animal studies have demonstrated improved viral clearance and cross‐protection upon lethal challenge in mice following passive M2 mAb transfer or M2‐immunized mice (reviewed in ref. \[[66](#B66){ref-type="ref"}\]). Phase I clinical safety trials evaluating VAX102, manufactured by VaxInnate, have reported increased M2e antibody responses \[[67](#B67){ref-type="ref"}\]. Creation of a universal influenza vaccine that targets conserved regions of the HA stem region is particularly appealing, and several groups have demonstrated encouraging results using broadly neutralizing mAb to regions of HA that are cross‐reactive between Group 1 and Group 2 influenza strains \[[68](#B68){ref-type="ref"}, [--](#B69){ref-type="ref"}, [70](#B70){ref-type="ref"}\]. Structural analyses indicate that these antibodies bind to conserved pockets of the A helix of the HA stalk, located below the trimeric head region \[[71](#B71){ref-type="ref"}, [--](#B72){ref-type="ref"}, [73](#B73){ref-type="ref"}\]. It is therefore within the realm of possibility to focus immunization strategies to these conserved regions in the HA and M2 proteins to elicit effective antibody, and presumably T cell, responses in the case of emergent influenza viruses. Still, it remains a mystery as to why these conserved epitopes have not generated a high level of cross‐protection in populations repeatedly immunized or infected with diverse viral strains.

IMMUNE RESPONSE TO INFLUENZA VIRUS INFECTION {#jlb0083-sec-0004}
============================================

Factors that limit influenza vaccine efficacy in humans include age, immunocompetence, and pre‐existing antibody levels from previous infections or immunizations. Whereas key lessons have been learned using animal models of influenza infection, studies done using human participants are invaluable for describing the unique and often complex characteristics of the human immune response to infection and immunization. Here, we describe central findings obtained from human influenza challenge studies, natural infections, and ex vivo characterization of human immune cells ([Table 1](#T1){ref-type="table"}). [Figure 1](#F1){ref-type="fig"} indicates where questions remain for the human immune response to infection.

###### 

Important Findings from Human Studies of Influenza Virus Infection

  Major findings                                                                                                     References
  ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Human challenge studies                                                                                            
      Main correlate of protection is neutralizing antibodies against HA.                                            \[[37](#B37){ref-type="ref"}, [47](#B47){ref-type="ref"}, [74](#B74){ref-type="ref"}, [--](#B75){ref-type="ref"}, [76](#B76){ref-type="ref"}, [77](#B77){ref-type="ref"}, [78](#B78){ref-type="ref"}, [79](#B79){ref-type="ref"}\], reviewed in ref. \[[80](#B80){ref-type="ref"}\]
  Evidence for heterosubtypic immunity                                                                               
      Pre‐existing immunity from previous influenza exposure elicits protection against heterologous infections.     \[[81](#B81){ref-type="ref"}, [--](#B82){ref-type="ref"}, [83](#B83){ref-type="ref"}, [84](#B84){ref-type="ref"}, [85](#B85){ref-type="ref"}, [86](#B86){ref-type="ref"}, [87](#B87){ref-type="ref"}, [88](#B88){ref-type="ref"}\]
      Broadly neutralizing antibodies to influenza                                                                   \[[68](#B68){ref-type="ref"}, [--](#B69){ref-type="ref"}, [70](#B70){ref-type="ref"}, [73](#B73){ref-type="ref"}, [89](#B89){ref-type="ref"}, [90](#B90){ref-type="ref"}\]
      Influenza‐specific T cells are cross‐reactive against heterologous strains.                                    \[[91](#B91){ref-type="ref"}, [--](#B92){ref-type="ref"}, [93](#B93){ref-type="ref"}, [94](#B94){ref-type="ref"}\]
  Dysregulated immune responses during influenza infection                                                           
      Increased cytokine levels during infection                                                                     \[[95](#B95){ref-type="ref"}, [--](#B96){ref-type="ref"}, [97](#B97){ref-type="ref"}, [98](#B98){ref-type="ref"}, [99](#B99){ref-type="ref"}, [100](#B100){ref-type="ref"}, [101](#B101){ref-type="ref"}, [102](#B102){ref-type="ref"}\]
      Infiltration of, or impaired chemotaxis of, leukocytes into the lung following infection                       \[[33](#B33){ref-type="ref"}, [96](#B96){ref-type="ref"}, [103](#B103){ref-type="ref"}, [--](#B104){ref-type="ref"}, [105](#B105){ref-type="ref"}, [106](#B106){ref-type="ref"}\]
      Low‐avidity antibodies and immune complexes in lungs of patients with severe disease                           \[[107](#B107){ref-type="ref"}\]
  Age‐dependent defects in adaptive immune responses                                                                 
      Reduced T cell infiltration or function in children                                                            \[[100](#B100){ref-type="ref"}, [108](#B108){ref-type="ref"}\]
      Subsequent influenza exposures are necessary for maturation of CTL responses in influenza‐naïve individuals.   \[[109](#B109){ref-type="ref"}\]
      Reduced CTL activity in elderly                                                                                \[[110](#B110){ref-type="ref"}, [--](#B111){ref-type="ref"}, [112](#B112){ref-type="ref"}, [113](#B113){ref-type="ref"}, [114](#B114){ref-type="ref"}, [115](#B115){ref-type="ref"}\]
  Genetic associations                                                                                               
      Indigenous people have more severe illness during A/H1N1 infections.                                           \[[29](#B29){ref-type="ref"}, [116](#B116){ref-type="ref"}, [--](#B117){ref-type="ref"}, [118](#B118){ref-type="ref"}\]
      SNPs within *FCGR2A*, *C1QBP*, and *MBL2* are associated with severe disease.                                  \[[119](#B119){ref-type="ref"}, [120](#B120){ref-type="ref"}\]
  Cellular immunity                                                                                                  
      Class I HLA presents peptides from internal and external viral proteins.                                       \[[121](#B121){ref-type="ref"}, [122](#B122){ref-type="ref"}\]

![A chronological profile of human influenza infection. Reported and suggested findings are highlighted in dark blue and light blue, respectively. Outstanding questions remain in white.](JLB-92-83-g001){#F1}

INNATE IMMUNITY {#jlb0083-sec-0005}
===============

Effective control and clearance of influenza infection can involve most components of the innate and adaptive immune responses. In mammals, the cellular innate immune system acts as a first‐line defense consisting of multipotent hematopoietic stem cells that differentiate into NK cells, mast cells, eosinophils, and basophils, as well as macrophages, neutrophils, and DCs, collectively known as phagocytic cells. Phagocytes function as APCs, engulfing and digesting opsonized pathogens and apoptotic cells. These cells essentially act as scavengers to uptake toxic metabolic byproducts and produce myriad inflammatory mediators, which ideally, result in the killing of viruses, bacteria, and parasites. However, abundant inflammation often has a role in creating immunopathology and can contribute to diverse inflammatory diseases, including asthma \[[123](#B123){ref-type="ref"}, [--](#B124){ref-type="ref"}, [125](#B125){ref-type="ref"}\].

In the absence of protective immune memory, the innate response limits initial viral replication, while the adaptive immune response develops. Influenza primarily infects epithelial cells lining the respiratory tract but can infect directly or be phagoctyosed by "professional" innate immune cells, DCs, and macrophages, which mature in response to viral stimuli or signals from other infected cells. After activation, mature DCs migrate to draining LNs, where they have a major role in antigen presentation to naïve T cells. Influenza infection of human monocyte‐derived DCs can result in decreased DC maturation from NS1 suppression of type I IFN production \[[126](#B126){ref-type="ref"}\]. Seasonal H1N1 viruses, including A(H1N1)pdm09, elicit weak, proinflammatory cytokine gene expression in human DCs \[[127](#B127){ref-type="ref"}\].

We know from murine models that influenza contains ligands that activate several PRR signaling pathways, including TLR3 and retinoic acid‐inducible gene I (RIG‐I), which recognize dsRNA, and TLR7, which recognizes ssRNA \[[128](#B128){ref-type="ref"}, [--](#B129){ref-type="ref"}, [130](#B130){ref-type="ref"}\]. Type I (IFN‐α/β) and type III (IFN‐λ1--λ3) IFNs mediate expression of more than 300 ISGs via the JAK/STAT pathway and are important in the induction of antiviral responses against influenza viruses \[[131](#B131){ref-type="ref"}\]. Stimulation of these pathways in DCs and macrophages leads to the induction of a potent antiviral response, including production of proinflammatory cytokines IL‐6 and IFN‐α within the respiratory tract by Day 2 following infection, paralleling the peak of viral replication, mucus production, and disease symptoms. TNF‐α and IL‐8 levels peak between Day 3 and 6 after infection as symptoms begin to subside \[[95](#B95){ref-type="ref"}\].

Antimicrobial peptides, such as collectins, defensins, and cathelicidins, are important innate effectors in the human defense against influenza infection. Collectins, or collagenous lectins, are found primarily in mucosal secretions and include SP‐A and SP‐D; SP‐D has been shown to inhibit HA activity by binding to N‐linked, high‐mannose oligosaccharides in a calcium‐dependent manner, while enhancing activation of neutrophils in in vitro assays \[[132](#B132){ref-type="ref"}, [133](#B133){ref-type="ref"}\]. In murine models, SP‐A and SP‐D have roles in promoting viral clearance from lungs and reducing inflammatory cytokines \[[134](#B134){ref-type="ref"}, [135](#B135){ref-type="ref"}\], but their role during human influenza infection is less well‐defined. Influenza virus impairs calcium metabolism and subsequent calcium deactivation in neutrophils \[[136](#B136){ref-type="ref"}\], and interestingly, SP‐D can protect neutrophils from calcium deactivation if preincubated with virus, presumably by inhibiting HA activity \[[132](#B132){ref-type="ref"}\]. In humans, the only cathelicidin, human cathelicidin 18, the active form of which is LL‐37, is found in diverse cell types, including neutrophils, NK cells, monocytes, B cells, γδ T cells, mast cells, as well as epithelial cells lining the lungs \[[137](#B137){ref-type="ref"}, [138](#B138){ref-type="ref"}\]. Like surfactants, LL‐37 shows antiviral activity against influenza and can reduce viral titers in in vitro studies \[[139](#B139){ref-type="ref"}\].

Defensins have a key role in host defense and act primarily to disrupt lipid membranes leading to lysis and subsequent death of bacteria, fungi, and enveloped viruses \[[140](#B140){ref-type="ref"}\]. There are two classes of defensins, α‐defensin and β‐defensin, which were first described in models of host defense against bacterial pathogens. Both types are found in the respiratory and gastrointestinal tracts. The α‐defensins in humans include HNP‐1, ‐2, ‐3, and ‐4, all found in high concentrations within neutrophil granules and released within the lungs in response to proinflammatory signals during infection and inflammation \[[141](#B141){ref-type="ref"}\]. In vitro, HNP‐1 and HNP‐2 act as chemokines for human monocytes \[[142](#B142){ref-type="ref"}\], and HNP‐1, ‐2, and ‐3 can induce neutrophil internalization of influenza in vitro \[[143](#B143){ref-type="ref"}\]. Moreover, the α‐defensins may have a role in directly inactivating influenza virus as A/WSN preincubated with HNP‐1 showed decreased infection in vitro in a dose‐dependent manner \[[144](#B144){ref-type="ref"}\]. HNP‐1 can also inhibit influenza virus replication via modulation of cellular pathways, including the PKC pathway \[[145](#B145){ref-type="ref"}\].

Heterogeneous populations of monocytes comprise ∼10% of blood leukocytes in humans (4% in the mouse), and their roles in controlling pathogens and inflammation can be characterized by functional cellular subsets. Human blood monocytes can be divided into three populations based primarily on cell surface expression of CD14 (LPS receptor) and CD16 (FcγRIII). The first subgroup consists of "classical monocytes", characterized by CD14 expression and lack of CD16 expression (CD14^+^CD16^−^). The CD14^+^CD16^−^ monocytes comprise 80--90% of blood monocytes and resemble murine inflammatory Ly6C^+^ (Gr1^+^) monocytes \[[146](#B146){ref-type="ref"}\]. The second subgroup is defined by high expression of CD14 and CD16 (CD14^+^CD16^+^) and release TNF following LPS stimulation \[[147](#B147){ref-type="ref"}\]. The third monocytic subgroup is characterized by low expression of CD14 and high expression of CD16 (CD14^dim^CD16^+^), and at least one study has shown increased numbers in the blood of sepsis patients \[[148](#B148){ref-type="ref"}\]. CD14^dim^ blood monocytes function as efficient producers of proinflammatory cytokines in response to viruses and nucleic acids \[[149](#B149){ref-type="ref"}, [150](#B150){ref-type="ref"}\]. Few studies have examined the role of monocytes during influenza infection in humans, particularly regarding the specific subsets mentioned above, but comparison of IFN‐γ production from T cells cocultured with CD64^+^CD16^−^ and CD64^−^CD16^+^ monocytes showed that CD64^−^CD16^+^ monocytes (equivalent to the CD14^+^CD16^+^ monocytes) induced a greater response to influenza A antigen \[[151](#B151){ref-type="ref"}\]. In vitro, human DCs and macrophages treated with type I or type III IFN prior to influenza infection result in potent antiviral activity and decreased viral replication \[[127](#B127){ref-type="ref"}\]. Among DC populations, CD11c^−^CD14^−^HLA‐DR^+^CD123^+^ pDCs were found to produce more IFN‐α in response to a high dose of A/PR8/8/34 (H1N1) \[[152](#B152){ref-type="ref"}\]. Whereas increased numbers of total CD14^+^ cells are observed in the blood of influenza‐infected individuals, decreased blood myeloid DCs and pDCs were observed (defined in this study as HLA‐DR^+^CD14^−^CD16^−^CD11c^+^ and HLA‐DR^+^CD14^−^CD16^−^CD123^+^, respectively) \[[153](#B153){ref-type="ref"}\]. However, increased numbers of pDCs were observed in nasal secretions compared with healthy controls within this cohort.

The NS1 protein is a well‐characterized antagonist of the hostˈs antiviral response, acting primarily to circumvent IFN‐α/β responses (reviewed in ref. \[[154](#B154){ref-type="ref"}\]), and in vivo models show that its deletion results in virus attenuation and higher levels of IFN \[[155](#B155){ref-type="ref"}\]. Type I IFN antagonism can result in inhibition of adaptive immunity by interfering with DC maturation and thus, the ability of DCs to activate T cells \[[126](#B126){ref-type="ref"}\]. The NS1 protein from influenza B virus inhibits ISGylation, an important host antiviral effector mechanism, by interacting with the N‐terminal domain of ISG15 \[[156](#B156){ref-type="ref"}\].

Murine models have provided several clues regarding the actual role of monocytes during the innate immune response to influenza infection. In vivo, CCR2‐dependent recruitment of inflammatory monocytes is critical for host defense and contributes to the innate immune response, as well as downstream adaptive responses \[[157](#B157){ref-type="ref"}\]. During influenza infection, CCR2‐deficient mice have reduced monocyte and increased neutrophil recruitment, but, despite higher viral lung titers, in one model of infection these mice were protected from severe pneumonitis \[[158](#B158){ref-type="ref"}, [159](#B159){ref-type="ref"}\]. In the lungs, CCR2‐mediated recruitment of TNF and iNOS‐producing DCs augments influenza‐specific T cell responses \[[160](#B160){ref-type="ref"}\]. At least one murine study suggests that pregnant mice have increased infiltration of neutrophils (CD11b^high^Ly6G^high^MHCII^−^) and macrophages (CD11b^high^Ly6G^−^MHCII^high^) and elevated, proinflammatory cytokine levels, despite no change in viral titers in the lungs compared with nonpregnant animals \[[161](#B161){ref-type="ref"}\]. In vitro, influenza infection of murine alveolar epithelial cells resulted in monocyte production of MCP‐1 (CCL2, the ligand for CCR2) and RANTES, and monocyte migration was dependent on CCR2 expression \[[162](#B162){ref-type="ref"}\]. Although some murine models suggest that neutrophils may have little role in mediating viral clearance \[[163](#B163){ref-type="ref"}\], type I interferon (IFN‐α/β)‐dependent generation of Ly6C^hi^ monocytes following influenza infection may be necessary to limit excess neutrophil infiltration, preventing tissue damage caused by uncontrolled inflammation \[[164](#B164){ref-type="ref"}\]. In addition, the newly described innate lymphoid cells have been implicated in having a role in airway integrity following influenza infection \[[165](#B165){ref-type="ref"}\]. Thus, innate immune cells, particularly monocytes, have at least two roles during influenza infection: to boost the innate immune response by producing proinflammatory cytokines and to enhance influenza‐specific T cell responses. However, the lack of clear correspondence between murine and human monocytic subsets has made the application of these data to the human situation difficult and highlights the need for specific studies focused on human innate immune responses.

During RSV and influenza infection of infants, neutrophils are recruited to the upper and lower airways in high numbers \[[103](#B103){ref-type="ref"}, [104](#B104){ref-type="ref"}\], and fatal cases during the A(H1N1)pdm09 pandemic with necrotizing bronchiolitis had more neutrophils within the lung infiltrate \[[33](#B33){ref-type="ref"}\]. The neutrophil chemoattractant IL‐8, produced by bronchial epithelial cells, is elevated early during experimental human influenza infection \[[95](#B95){ref-type="ref"}\] and is increased in the serum of A/H5N1‐infected individuals \[[96](#B96){ref-type="ref"}\]. Increased IL‐8 levels in BALs of humans are associated with the infiltration of neutrophils and may have a role in neutrophil‐mediated lung injury and development of acute respiratory distress syndrome \[[97](#B97){ref-type="ref"}\]. Ex vivo influenza infection of PBMCs has been shown to induce apoptosis in neutrophils \[[166](#B166){ref-type="ref"}\] and peripheral blood monocytes \[[167](#B167){ref-type="ref"}\]. Influenza infection of neutrophils resulted in increased hydrogen peroxide production, enhanced surface expression of Fas antigen and FasL, and secretion of FasL into the supernatant \[[166](#B166){ref-type="ref"}\]. Interestingly, this study showed that influenza infection of neutrophils resulted in increased internalization of *Escherichia coli*, suggesting a role in controlling bacterial secondary infections in humans. Moreover, standard chemotaxis assays during experimental influenza infection \[[168](#B168){ref-type="ref"}, [--](#B169){ref-type="ref"}, [170](#B170){ref-type="ref"}\] or chemokine receptor expression during ex vivo influenza infection \[[105](#B105){ref-type="ref"}\] demonstrated impaired chemotaxis of monocytes and granulocytes. Still, although all of these studies suggest that neutrophils can be regulated and recruited during human influenza infection, the specific protective and pathological roles that they play in vivo remain unclear.

Nasopharygeal aspirates of infants infected with influenza have increased levels of proinflammatory cytokines such as IL‐6, TNF‐α, IL‐10, or IFN‐γ compared with RSV‐ or human metapneumovirus‐infected infants \[[98](#B98){ref-type="ref"}, [--](#B99){ref-type="ref"}, [100](#B100){ref-type="ref"}\], and MIP‐1α levels are higher in infants with more severe influenza infections characterized by hypoxic bronchiolitis \[[101](#B101){ref-type="ref"}\]. Variability between these studies is likely a result of seasonal differences observed year‐to‐year. Individuals infected with A/H5N1 have high viral loads detected within respiratory secretions and peripheral hypercytokinemia \[[96](#B96){ref-type="ref"}, [102](#B102){ref-type="ref"}\]. Severe disease is associated with macrophage infiltration into the lungs, and chemoattractants of monocytes and macrophages, such as IFN‐inducible protein 10 (IP‐10), monokine induced by IFN‐γ (MIG), and MCP‐1, were found to be elevated in the serum of influenza‐infected individuals and were highest in those infected with A/H5N1 \[[96](#B96){ref-type="ref"}\]. Therefore, peripheral (or local) hypercytokinemia likely contributes to enhanced immunopathogenesis during influenza disease. Although there is no difference in the duration of viral shedding in children hospitalized for A/H1N1 or A/H3N2 infections compared with those infected with influenza B virus, children with influenza A exhibited different serum cytokine profiles. Serum IFN‐γ levels were similar during acute‐phase infection \[[171](#B171){ref-type="ref"}\], but levels were increased 3 weeks following influenza B infection compared with influenza A infection. Furthermore, serum IL‐4 levels were significantly higher during the acute and recovery phases of influenza A infection. Influenza strain differences were also observed in umbilical cord blood lymphocytes treated with UV‐inactivated viruses. UV‐inactivated influenza B virus induced less IFN‐γ, IL‐4, or IL‐10 relative to UV‐inactivated A/H1N1, A/H3N2, and A/H2N2 \[[172](#B172){ref-type="ref"}\].

Together, these data strongly suggest that innate cells and their associated responses have an important role in influenza disease manifestation, by providing protection and by contributing to pathological outcomes. The murine studies cited here clearly demonstrate that the local inflammatory environment can be dramatically different from the blood profile. The vast majority of experimental data in humans is restricted to blood leukocytes, with minimal emphasis placed on sites of infection. Further, we lack good, functional analysis of these cells in humans, and most studies provide correlational, cross‐sectional observations. As a result, there is a significant gap in our knowledge of innate immune cells in affected tissues.

ROLE OF ANTIBODY‐MEDIATED IMMUNITY IN HUMANS {#jlb0083-sec-0006}
============================================

The history of respiratory virus challenge studies dates back to the 1918 influenza pandemic \[[173](#B173){ref-type="ref"}\], and early studies in humans infected with influenza identified the principal correlate of protection against influenza infection as strain‐specific, virus‐neutralizing antibodies directed against the HA. These studies (reviewed in ref. \[[80](#B80){ref-type="ref"}\]) suggested that the presence of serum antibody is associated with protection, as illness is less frequently observed in those people with pre‐existing nAb \[[74](#B74){ref-type="ref"}\]. Subsequent studies showed that protection is also correlated with the development of serum and mucosal anti‐NA or anti‐HA IgG and IgA \[[37](#B37){ref-type="ref"}, [47](#B47){ref-type="ref"}, [75](#B75){ref-type="ref"}, [--](#B76){ref-type="ref"}, [77](#B77){ref-type="ref"}, [78](#B78){ref-type="ref"}\], but this protection can be incomplete, as individuals with detectable nAb can still be infected \[[79](#B79){ref-type="ref"}, [174](#B174){ref-type="ref"}\]. Antibodies specific for the NA have been shown to reduce disease severity by restricting virus release from infected cells and enhancing viral clearance (reviewed in ref. \[[175](#B175){ref-type="ref"}\]). In addition to HA and NA, antibodies are produced to NP, matrix M2 protein, and PB1‐F2 \[[176](#B176){ref-type="ref"}\], although the significance of these responses remains unclear. Of course, antigenic shift and antigenic drift can both thwart the efficacy of serological memory.

The recent circulation of A(H1N1)pdm09 has provided a modern "experiment of nature", demonstrating the importance of pre‐existing antibody from prior infection or vaccination \[[81](#B81){ref-type="ref"}, [--](#B82){ref-type="ref"}, [83](#B83){ref-type="ref"}\]. Even prior to 2009, it was well‐recognized that heterosubtypic immunity has a large role in protection against antigenic variants of influenza \[[84](#B84){ref-type="ref"}, [85](#B85){ref-type="ref"}\], and vaccine studies support the idea that cross‐protective, adaptive immune responses occur \[[86](#B86){ref-type="ref"}\]. Likewise, neutralizing polyclonal antibodies cross‐reactive against H5 can also be produced in individuals vaccinated against seasonal influenza, as well as those naturally infected with A(H1N1)pdm09 \[[87](#B87){ref-type="ref"}, [88](#B88){ref-type="ref"}\]. Compared with seasonal influenza infections prior to 2009, ∼31% of B cell epitopes are conserved in A(H1N1)pdm09, with 17% of those conserved within the surface viral proteins \[[177](#B177){ref-type="ref"}\]. The HA of A(H1N1)pdm09 contains sequences homologous with that of A/H1N1 (1918) demonstrated by the A/H1N1 (1918) mAb 2D1, which binds to the Sa antigenic site of the HA \[[89](#B89){ref-type="ref"}\]. Furthermore, this particular antibody can neutralize HA activity in vitro, and mAb‐treated mice show reduced viral titers when challenged with A(H1N1)pdm09 \[[90](#B90){ref-type="ref"}\]. Most neutralizing antibodies bind to the exposed regions of the HA that surround the receptor‐binding site and interfere with attachment to sialic acids on the cell surface. Therefore, generation of cross‐protective neutralizing antibodies is elusive, as the external viral proteins are most exposed to immune pressure, but universal immunization against conserved HA stalk and M2e domains is promising \[[71](#B71){ref-type="ref"}, [--](#B72){ref-type="ref"}, [73](#B73){ref-type="ref"}\].

CELL‐MEDIATED IMMUNITY IN HUMANS {#jlb0083-sec-0007}
================================

Human PBMCs include at least three major subsets of DCs: CD141^+^ mDCs, CD1c^+^ mDCs, and pDCs (reviewed in ref. \[[178](#B178){ref-type="ref"}\]). DCs process and present antigen to T cells and therefore have an important role in regulating the adaptive immune response. Depending on the local cytokine milieu, mDCs can differentiate into macrophages or tissue‐specific DCs (i.e., epithelial Langerhans cells or interstitial DCs). As influenza primarily infects epithelial cells lining the respiratory tract, lung‐resident DCs and macrophages are particularly important for efficient development of an adaptive immune response. Once activated, mDCs function as APCs to activate T cells; on the other hand, pDCs are major producers of type I IFN upon TLR activation. In response to influenza infection in vitro, human DCs and macrophages undergo maturation, secreting type I IFN and inducing T cell proliferation and IFN‐γ production \[[179](#B179){ref-type="ref"}, [--](#B180){ref-type="ref"}, [181](#B181){ref-type="ref"}\].

Cellular immune responses (CD8^+^ CTLs and CD4^+^ Th cells) are important for virus clearance in murine models of influenza infection, with CD4^+^ and CD8^+^ T cell‐depleted mice displaying delayed viral clearance. The relevance of these observations remains somewhat controversial in humans. Regardless, as in mice, the human lung contains resident respiratory virus‐specific CD8^+^ memory T cells \[[182](#B182){ref-type="ref"}\], which can effectively kill virus‐infected cells. Human CD8^+^ T cells recognize antigen in the context of surface HLA molecules and generally recognize a broad range of influenza epitopes, including those from structural and nonstructural influenza proteins \[[121](#B121){ref-type="ref"}\]. Approximately 41% of CD4^+^ and 69% of CD8^+^ T cell epitopes are conserved in A(H1N1)pdm09 from the prior circulating seasonal H1N1 \[[177](#B177){ref-type="ref"}\]. Furthermore, CD8^+^ intraepithelial T cells can mount fast and efficient recall responses upon viral infection \[[183](#B183){ref-type="ref"}\], and immunization studies in humans have shown that T cell responses peak within 1 week after symptom onset \[[174](#B174){ref-type="ref"}\]. In terms of pandemic viruses, individuals infected with A(H1N1)pdm09 were shown to have rapid, virus‐specific CD8^+^ T cell recall responses early during infection, but this CTL response wanes over time \[[184](#B184){ref-type="ref"}\]. Likewise, vaccinated individuals, who were then naturally infected with A(H1N1)pdm09, had T cell responses increase by twofold early after infection \[[174](#B174){ref-type="ref"}\]. Memory CD4^+^ or CD8^+^ T cells isolated from PBMCs of healthy individuals are also cross‐reactive against proteins of heterologous viruses, including those from A(H1N1)pdm09 and A/H5N1 \[[91](#B91){ref-type="ref"}, [--](#B92){ref-type="ref"}, [93](#B93){ref-type="ref"}, [94](#B94){ref-type="ref"}\], but immunocompromised patients do not have lasting antibody or CD4^+^/CD8^+^ memory responses following natural A(H1N1)pdm09 infection \[[185](#B185){ref-type="ref"}\]. Furthermore, CTLs, isolated from A(H1N1)pdm09‐ or A/H5N1‐inexperienced individuals with a memory CD45RA^med^CD62 ligand^lo^CCR7^−^ phenotype, will respond robustly to peptide pools and influenza‐infected cells \[[34](#B34){ref-type="ref"}, [177](#B177){ref-type="ref"}, [186](#B186){ref-type="ref"}, [187](#B187){ref-type="ref"}\], suggesting that T cells may provide some level of protection against conserved epitopes \[[110](#B110){ref-type="ref"}\]. Although nonconserved regions of the virus may effectively escape recognition by T cells \[[188](#B188){ref-type="ref"}\], the majority of T cell responses is elicited against conserved, internal viral proteins, generating much interest in vaccine or therapeutic strategies that involve T cell‐mediated immunity.

A frequently neglected population of lymphocytes, γδ T cells comprise 1--5% of T cells in the blood of humans, the majority of which are Vγ9Vδ2 T cells. These γδ T cells are considered to be a major innate‐like T cell subset (reviewed in ref. \[[189](#B189){ref-type="ref"}\]), and in vitro studies suggest that activated human Vγ9Vδ2 T cells may have a role in the antiviral response by killing influenza‐infected, monocyte‐derived macrophages and producing high levels of IFN‐γ \[[190](#B190){ref-type="ref"}, [191](#B191){ref-type="ref"}\].

CELLULAR RESPONSES IN AT‐RISK POPULATIONS {#jlb0083-sec-0008}
=========================================

In particular, neonates are known to have compromised cellular immune responses and represent an important target population for influenza immunization. Despite being such a critical target population, there are relatively few neonatal models of respiratory infections, and for ethical reasons, it is appropriately difficult to acquire data from human neonates. In the case of RSV infection, murine neonate models suggest that the age of primary viral infection can determine the immunopathology of a secondary viral infection \[[192](#B192){ref-type="ref"}, [--](#B193){ref-type="ref"}, [194](#B194){ref-type="ref"}\]. During RSV infection, younger murine neonates (≤7 days) will develop an immune response characterized by increased eosinophil and T cell recruitment to the lungs, enhanced airway hyper‐responsiveness, and higher IL‐13 levels upon reinfection 12 weeks later, whereas older mice (≥4 weeks) develop an immune response characterized by decreased T cell and eosinophil recruitment to the lungs upon reinfection \[[192](#B192){ref-type="ref"}, [193](#B193){ref-type="ref"}\]. Likewise, a neonatal mouse model of influenza A virus showed that early infection was associated with decreased CD8^+^ T cell recruitment and function and enhanced airway inflammation \[[195](#B195){ref-type="ref"}\]. These studies highlight an important concept, whereby infection too early results not in protective immunity but immunopathogenesis. Consistent with an age‐dependent defect in adaptive immunity, during RSV and influenza infection of infants, few CD4^+^ or CD8^+^ T cells or CD56^+^ NK cells are found in the upper and lower airways \[[100](#B100){ref-type="ref"}, [103](#B103){ref-type="ref"}, [104](#B104){ref-type="ref"}\], in contrast to the observed infiltration of lymphocytes in adult A/H5N1 influenza \[[106](#B106){ref-type="ref"}\] and SARS CoV infections \[[196](#B196){ref-type="ref"}, [197](#B197){ref-type="ref"}\]. Moreover, fatal cases of A(H1N1)pdm09 had increased numbers of CD8^+^ T cells and granzyme B^+^ cells in their lungs \[[33](#B33){ref-type="ref"}\]. This observation may represent a correlation with higher levels of viral antigen or may indicate a pathogenic role of exuberant CD8^+^ T cell responses. On the other hand, the elderly have been shown to have reduced CTL activity compared with younger individuals, and this can have a negative impact on immunization efficacy \[[111](#B111){ref-type="ref"}, [--](#B112){ref-type="ref"}, [113](#B113){ref-type="ref"}\]. However, prevaccination T cell responses do not correlate with postvaccination antibody titers \[[114](#B114){ref-type="ref"}\], and as the elderly also have decreased antibody responses following vaccination, T cell responses may provide a better correlate of vaccine efficacy in the elderly population \[[115](#B115){ref-type="ref"}\]. Interestingly, unstimulated memory T cells from older individuals are in a higher state of differentiation than those of younger individuals, and it was shown that fewer senescent, influenza‐specific T cells, characterized as killer cell lectin‐like receptor subfamily G member 1 (KLRG1)^hi^CD57^hi^, are associated with a more robust antibody response following TIV delivery \[[110](#B110){ref-type="ref"}\].

The immunodominance hierarchy in HLA‐A\*02 individuals is often reported as directed primarily against the conserved influenza A M1~58--66~ (GILGFVFTL) \[[198](#B198){ref-type="ref"}, [199](#B199){ref-type="ref"}\]. However, studies suggest that although this CD8^+^ T cell response to M1~58--66~ is conserved in HLA‐A\*02 individuals, it may not be strictly immunodominant, as greater responses were observed against internal NP and polymerase PB1 subunit proteins in some individuals \[[122](#B122){ref-type="ref"}, [200](#B200){ref-type="ref"}\]. In terms of HLA presentation of influenza peptides, the HLA‐A\*02:01‐restricted M1~58--66~ peptide‐specific CTL response is characterized by expression of V~β~17 TCR use \[[201](#B201){ref-type="ref"}\], and in HLA‐A\*02:01 individuals, V~β~17^+^ CTLs were the dominant cells responding to in vitro influenza exposure. In contrast, cord blood from HLA‐A\*02:01 infants, thus having no prior influenza exposure, was characterized by a M1~58--66~‐specific CD8^+^ T cell response that was less dependent on the presence of the CD8^+^V~β~17^+^ T cell population \[[109](#B109){ref-type="ref"}\]. Therefore, maturation of the CTL response upon subsequent influenza infections is likely related to effective clearance of viral infections and has important implications for therapeutic interventions. Although children beyond infancy who are considered high‐risk for influenza infection, i.e., children with underlying diseases, such as asthma, sickle cell disease, and those receiving solid organ transplantation, have significant increases in serum nAb and T cell responses, children with systemic lupus erythematosus are unable to mount significant T cell responses following TIV immunization \[[108](#B108){ref-type="ref"}\]. These findings suggest that the pathogenesis of respiratory viral infections in infants may be associated with the absence of immunological memory or a failure to develop an appropriate, well‐regulated T cell response.

GENETIC ASSOCIATIONS WITH SEVERE INFLUENZA INFECTIONS {#jlb0083-sec-0009}
=====================================================

Undoubtedly, host genetics have a role in the outcome of many infectious diseases, including influenza. Mouse models have provided some clues regarding the role of the host genetic component on the inflammatory response in the respiratory tract. Briefly, these studies found that influenza‐induced pathology is altered depending on the inbred mouse strain used for infection. The genetic background of the host also controls cumulative and maximal viral titer, underscoring the importance of limiting viral replication early during influenza infection \[[111](#B111){ref-type="ref"}, [202](#B202){ref-type="ref"}\].

In humans, certain populations worldwide have been found to be more prone to severe disease during influenza infection. For instance, Aboriginal peoples have more severe illness and increased mortality during the A/H1N1 pandemics of 1918 and 2009 compared with those of non‐Aboriginal descent \[[29](#B29){ref-type="ref"}, [116](#B116){ref-type="ref"}, [--](#B117){ref-type="ref"}, [118](#B118){ref-type="ref"}\]. It is important to note, however, that poor socioeconomic conditions and metabolic diseases, such as diabetes, are more common in indigenous populations \[[203](#B203){ref-type="ref"}\], and this may contribute to influenza‐related disease. Moreover, HLA alleles are proposed to have some role during influenza infection, as differential CTL responses exist in individuals with varying HLA alleles \[[204](#B204){ref-type="ref"}\].

Gene polymorphisms located in human chromosomes 1 and 17 were also determined to be associated with severe pneumonia during A(H1N1)pdm09 infection \[[120](#B120){ref-type="ref"}\]. Interestingly, two of these SNPs are mapped to genes *FCGR2A* and *C1QBP*. The protein encoded by *FCGR2A* is involved in phagocytosis and clearance of immune complexes and expressed on the surface of phagocytic cells. The protein encoded by *C1QBP* is a critical factor involved in complement activation. Notably, presence of low‐avidity antibodies and subsequent formation of immune complex‐mediated complement activation in the lungs of patients with severe influenza infection are associated with severe disease following influenza infection \[[107](#B107){ref-type="ref"}\]. Recently, "systems biology" strategies have emerged to improve vaccine efficacy, measuring expression patterns to expose protective molecular signatures following immunization or natural infection \[[46](#B46){ref-type="ref"}, [205](#B205){ref-type="ref"}\].

Confirming in vitro mouse studies, which suggest that MBL can neutralize influenza \[[206](#B206){ref-type="ref"}, [207](#B207){ref-type="ref"}\], human polymorphisms identified within *MBL2* are associated with poor antibody responses to influenza vaccination \[[119](#B119){ref-type="ref"}\]. Although MBL deficiency has been observed to influence the outcome in several respiratory diseases, including pneumococcus infection, tuberculosis, and SARS CoV (reviewed in ref. \[[208](#B208){ref-type="ref"}\]), it did not have an obvious role in A(H1N1)pdm09 infection of naïve individuals \[[209](#B209){ref-type="ref"}\]. These studies highlight the involvement of host genetics in development of enhanced disease, although they likely represent a small fraction of the potential regulatory host genetic elements.

CONCLUSION {#jlb0083-sec-0010}
==========

Studies of innate and adaptive immune responses to influenza virus infection have been restricted primarily to animal models of disease and inflammation. As our immunological tools become more sophisticated, more emphasis should be placed on human immunology as opposed to relying solely on animal infection models. Moreover, the vast majority of experimental data in humans is restricted to blood leukocytes, with minimal emphasis placed on the innate immune response, particularly at sites of infection. As a result, there is limited scientific knowledge regarding the specific roles of immune cells in affected tissues. Understanding the innate response in particular is critical to appreciate early determinants of pathogenicity and disease outcome during influenza infection.
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